Presentation (CTI)

OBJECTIVES: Biologic therapies are increasingly integrated into multiple myeloma (MM), intensifying demands on oncology services. Conventional manual subcutaneous (SC) syringe administration remains labour-intensive and may limit the full value of biologic therapies through inefficiencies in preparation, administration, and service delivery. This study evaluated how on-body injectors (OBIs) may enhance MM care value by improving healthcare efficiency, reducing workforce burden, and supporting sustainable service delivery.
METHODS: A targeted literature review was conducted using Embase, Ovid MEDLINE, Ovid Nursing Database, grey literature and nursing-focused publications to identify evidence on challenges associated with current SC administration and the impact of OBIs in oncology. Evidence was synthesised thematically across healthcare professional (HCP) and health system domains, focusing on workflow efficiency, operational capacity, occupational burden, and value generation.
RESULTS: Conventional SC administration involves multiple resource-intensive processes, including biological warming, aseptic preparation, syringe priming, cold-chain management, and manual injection, creating substantial pharmacy and nursing workload. Evidence suggests that OBIs simplify administration pathways by reducing manual preparation and injection requirements. Evidence also suggests that HCPs typically report strong preferences for OBI systems due to ease of use and lower physical burden. Compared to manual SC administration, OBIs are likely to reduce repetitive strain, needlestick injuries, and occupational exposure during drug handling. By reducing patient anxiety and administration complexity, OBIs are considered to improve clinical workflow efficiency and lessen staff counselling requirements. At the health system-level, hands-free administration is likely to optimise treatment throughput, increase infusion centre capacity, improve workforce productivity, and support decentralised care delivery. Collectively, these effects extend the value of biologic therapies beyond clinical outcomes by enhancing healthcare efficiency and reducing resource utilisation.
CONCLUSIONS: OBIs represent a promising administration innovation capable of unlocking additional patient, workforce, and health system value in MM care. Wider adoption may improve healthcare efficiency, strengthen oncology service sustainability, and support higher-value cancer care delivery.